MP54-15 A MULTICENTER STUDY OF 2-YEAR OUTCOMES FOLLOWING HYPERTHERMIA THERAPY WITH MITOMYCIN C IN TREATING BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: RECIRCULANT HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY

You have accessJournal of UrologyCME1 May 2022MP54-15 A MULTICENTER STUDY OF 2-YEAR OUTCOMES FOLLOWING HYPERTHERMIA THERAPY WITH MITOMYCIN C IN TREATING BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: RECIRCULANT HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY Andrew Stemberger, Wei Phin Tan, Ana Plata Bello, Juan Carlos Garcia Alvarez, Félix Guerrero-Ramos, Daniel A. González-Padilla, Cajetan Nzeh, Jose Manuel de la Morena, Ignacio Gonzalez Valcarcel de Torres, Kees Hendricksen, Francisco Javier Díaz-Goizueta, J. Fernandez Del Alamo, Francesco Chiancone, Paolo Fedelini, Massimiliano Poggio, Francesco Porpiglia, Victoria C. Gonzalo Rodríguez, Javier Montero Torres, Daniel Wilby, Richard Robinson, Alejandro Sousa-Escandón, Juan León-Mata, Jose L. Pontones Moreno, Francisco Delgado Molina, Miguel A. Adriazola Semino, Jesús Calleja-Escudero, Joan Palou Redorta, and Wei Shen Tan Andrew StembergerAndrew Stemberger , Wei Phin TanWei Phin Tan , Ana Plata BelloAna Plata Bello , Juan Carlos Garcia AlvarezJuan Carlos Garcia Alvarez , Félix Guerrero-RamosFélix Guerrero-Ramos , Daniel A. González-PadillaDaniel A. González-Padilla , Cajetan NzehCajetan Nzeh , Jose Manuel de la MorenaJose Manuel de la Morena , Ignacio Gonzalez Valcarcel de TorresIgnacio Gonzalez Valcarcel de Torres , Kees HendricksenKees Hendricksen , Francisco Javier Díaz-GoizuetaFrancisco Javier Díaz-Goizueta , J. Fernandez Del AlamoJ. Fernandez Del Alamo , Francesco ChianconeFrancesco Chiancone , Paolo FedeliniPaolo Fedelini , Massimiliano PoggioMassimiliano Poggio , Francesco PorpigliaFrancesco Porpiglia , Victoria C. Gonzalo RodríguezVictoria C. Gonzalo Rodríguez , Javier Montero TorresJavier Montero Torres , Daniel WilbyDaniel Wilby , Richard RobinsonRichard Robinson , Alejandro Sousa-EscandónAlejandro Sousa-Escandón , Juan León-MataJuan León-Mata , Jose L. Pontones MorenoJose L. Pontones Moreno , Francisco Delgado MolinaFrancisco Delgado Molina , Miguel A. Adriazola SeminoMiguel A. Adriazola Semino , Jesús Calleja-EscuderoJesús Calleja-Escudero , Joan Palou RedortaJoan Palou Redorta , and Wei Shen TanWei Shen Tan View All Author Informationhttps://doi.org/10.1097/JU.0000000000002633.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Bacillus Calmette–Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) is a challenging disease to manage. We aim to evaluate the recurrence-free survival (RFS) and progression free survival (PFS) of patients treated with chemo hyperthermia (CHT) with mitomycin C using the Combat bladder recirculation system. METHODS: We retrospectively evaluated the Hyperthermic Chemotherapy registry - a prospective, multi-institutional registry of 1,028 patients with NMIBC, confirmed on transurethral resection of bladder tumor, who underwent CHT between 2012 and 2020. Mitomycin C is heated to 43 °C using an aluminum heat exchanger that enables efficient heat transfer and accurate temperature control within ±0.5 °C. RESULTS: There was a total of 174 were patients who had BCG unresponsive disease and were treated with CHT with Mitomycin C. Median follow up was 16.8 months (Interquartile range (IQR): 9.1 – 26.0). Median age was 68.9 years (IQR: 59.8 – 76.2). A total of 141 (81.0%) patients were men and 33 (19.0%) were women. RFS at 12 and 24 months were 78.1% (95% CI 72% – 84.7%) and 57.4% (95% CI 49.7% – 66.3%), respectively. The PFS at 12 months and 24 months were 95.2% (95% CI 91.8% – 98.7%) and 90.1% (95% CI 84.8% and 95.8%), respectively. On subgroup analysis of the BCG unresponsive cohort by the presence of CIS, the RFS at 12 months was 69.5% (95% CI 58.1% – 83.2%) in the CIS positive with/without papillary group and 82.2% (95% CI 75.4% – 89.6%) in the CIS negative with papillary only group. The RFS at 24 months was 43.6% (95% CI 31.4% – 60.4%) in the CIS positive with/without papillary group and 64.5% (95% CI 55.4% – 75.1%) CIS negative with papillary only group. Minor adverse events occurred in 33 (19.2%) of patients and severe events occurred in 2 (1.1%). CONCLUSIONS: CHT with MMC using the Combat BRS is effective in the medium term and has a favorable adverse event profile in BCG unresponsive patients. This may represent an attractive treatment option in a space where there are limited treatment options available. Source of Funding: Registry maintained by Combat Medical © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e932 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Andrew Stemberger More articles by this author Wei Phin Tan More articles by this author Ana Plata Bello More articles by this author Juan Carlos Garcia Alvarez More articles by this author Félix Guerrero-Ramos More articles by this author Daniel A. González-Padilla More articles by this author Cajetan Nzeh More articles by this author Jose Manuel de la Morena More articles by this author Ignacio Gonzalez Valcarcel de Torres More articles by this author Kees Hendricksen More articles by this author Francisco Javier Díaz-Goizueta More articles by this author J. Fernandez Del Alamo More articles by this author Francesco Chiancone More articles by this author Paolo Fedelini More articles by this author Massimiliano Poggio More articles by this author Francesco Porpiglia More articles by this author Victoria C. Gonzalo Rodríguez More articles by this author Javier Montero Torres More articles by this author Daniel Wilby More articles by this author Richard Robinson More articles by this author Alejandro Sousa-Escandón More articles by this author Juan León-Mata More articles by this author Jose L. Pontones Moreno More articles by this author Francisco Delgado Molina More articles by this author Miguel A. Adriazola Semino More articles by this author Jesús Calleja-Escudero More articles by this author Joan Palou Redorta More articles by this author Wei Shen Tan More articles by this author Expand All Advertisement PDF downloadLoading ...